到 2027 年美国前列腺癌核医学诊断市场 - 按类型分类的国家分析和预测(SPECT、PET); PET 产品(F-18、C11、GA 68 PSMA)

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027


No. of Pages: 69    |    Report Code: TIPRE00009805    |    Category: Life Sciences

US Prostate Cancer Nuclear Medicine Diagnostics Market

2019年美国前列腺癌核医学诊断市场价值为1.9447亿美元,预计2020年至2027年复合年增长率为10.6%,到2027年将达到4.3176亿美元2027.

 

前列腺癌正在影响男性的前列腺。前列腺癌是男性继皮肤癌之后的常见癌症。导致前列腺癌发生的一些常见决定因素是家族史、老年和种族。核医学是需要放射性材料的成像。它是识别和治疗前列腺癌的有效方法,并帮助放射科医生确定癌症的分期。美国前列腺癌核医学诊断市场受到前列腺癌患病率上升等因素的推动,而创新放射性药物的增长对放射性药物市场的增长起着至关重要的作用。然而,严格的储存、生产和使用指南在预测期内,放射性药物的使用可能会阻碍美国前列腺癌核医学诊断市场的增长。

 

2027年美国前列腺癌核医学诊断市场收入及预测(百万)




 

市场洞察

前列腺癌患病率上升

就发生率而言,前列腺癌 (PCa) 是美国第四大常见癌症。该国前列腺癌患病率不断上升,导致越来越多地使用核药物进行治疗。例如,根据 GLOBOCAN 的数据,2018 年美国约有 2,129,118 例癌症病例。其中,约10%为前列腺癌,2018年发病人数为212,783人。此外,该国报告有28,705人因癌症死亡。该组织估计,未来五年前列腺癌病例将达到 737,463 例以上。继皮肤癌之后,前列腺癌是美国男性中最常见的癌症。根据美国癌症协会2020年的数据,预计2020年美国前列腺癌患者约为191,930人,约33,330人死于前列腺癌。前列腺癌更容易在老年人中生长。近十分之六的病例是在 65 岁或以上的男性中发现的。美国男性的平均识别年龄约为 66 岁。在开始额外治疗之前需要检查前列腺癌。并采用核医学进行诊断和分析思路。 PET 和 SPECT 中的核医学具有治疗和诊断前景。因此,由于前列腺癌发病率的上升,前列腺癌核医学诊断市场在整个预测期内增加的可能性很大。

 

类型洞察

根据类型,美国前列腺癌核医学诊断市场分为 PET 和 SPECT。与传统 SPECT 核医学诊断流程相比,PET 细分市场由于具有更高的图像质量和复杂的程序报销,在 2019 年占据了最大的市场份额。用于 PET 前列腺癌诊断的放射性同位素有氟 18、镓 68、铜 64、锆 89 和胆碱 11。此外,预计同一细分市场在预测期内的复合年增长率最高。

 

PET 产品洞察

美国前列腺癌核医学诊断市场,按PET产品分为F-18、C-11和Ga68-PSMA。 F-18 细分市场在 2019 年占据最大市场份额。然而,由于前列腺癌患病率上升、诊断技术改进等因素,预计 Ga68-PSMA 在预测期内的市场复合年增长率最高

       

战略洞察

公司通常采用产品发布和 FDA 批准策略来扩大其在全球的足迹并满足不断增长的需求要求。这种策略最常被市场参与者采用,以扩大其产品组合。

在美国前列腺癌核医学诊断市场运营的市场参与者采取合作策略扩大全球客户群,这也使玩家能够维持自己的品牌名称。

 

美国前列腺癌核医学诊断市场 –按类型

  • PET
  • SPECT

美国前列腺癌核医学诊断市场 –按PET产品

  • F-18
  • C-11
  • Ga68-PSMA

公司简介

  • Blue Earth Diagnostics Limited
  • Progenics Pharmaceuticals, Inc.
  • CURIUM
  • Telix Pharmaceuticals Ltd.
  • NCM-USA LLC
  • ABX Advanced BiochemicalCompounds GmbH< /span>
  • Jubilant Radiopharma
  • Lantheus Medical Imaging, Inc.
  • 高级加速器应用(诺华公司)
  • 治疗学


US Prostate Cancer Nuclear Medicine Diagnostics Strategic Insights

Strategic insights for US Prostate Cancer Nuclear Medicine Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/us-prostate-cancer-nuclear-medicine-diagnostics-market-strategic-framework.webp
Get more information on this report

US Prostate Cancer Nuclear Medicine Diagnostics Report Scope

Report Attribute Details
Market size in 2019 US$ 194.47 Million
Market Size by 2027 US$ 431.76 million
Global CAGR (2020 - 2027) 10.6%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By 类型
  • SPECT
  • PET
By PET 产品
  • F-18
  • C11
  • GA 68 PSMA
Regions and Countries Covered 美国
  • 美国
Market leaders and key company profiles
  • Blue Earth Diagnostics Limited
  • Progenics Pharmaceuticals, Inc.
  • CURIUM
  • Telix Pharmaceuticals Ltd.
  • NCM-USA LLC
  • ABX Advanced Biochemical Compounds GmbH
  • Jubilant Radiopharma
  • Lantheus Medical Imaging, Inc.
  • Advanced Accelerator Applications (Novartis AG)
  • Theragnostics
  • Get more information on this report

    US Prostate Cancer Nuclear Medicine Diagnostics Regional Insights

    The regional scope of US Prostate Cancer Nuclear Medicine Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/us-prostate-cancer-nuclear-medicine-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - US Prostate Cancer Nuclear Medicine Diagnostics Market

    The List of Companies - US Prostate Cancer Nuclear Medicine Market

    1. Blue Earth Diagnostics Limited
    2. Progenics Pharmaceuticals, Inc.
    3. CURIUM
    4. Telix Pharmaceuticals Ltd.
    5. NCM-USA LLC
    6. ABX Advanced Biochemical Compounds GmbH
    7. Jubilant Radiopharma
    8. Lantheus Medical Imaging, Inc.
    9. Advanced Accelerator Applications (Novartis AG)
    10. Theragnostics

     

    Frequently Asked Questions
    How big is the US Prostate Cancer Nuclear Medicine Diagnostics Market?

    The US Prostate Cancer Nuclear Medicine Diagnostics Market is valued at US$ 194.47 Million in 2019, it is projected to reach US$ 431.76 million by 2027.

    What is the CAGR for US Prostate Cancer Nuclear Medicine Diagnostics Market by (2020 - 2027)?

    As per our report US Prostate Cancer Nuclear Medicine Diagnostics Market, the market size is valued at US$ 194.47 Million in 2019, projecting it to reach US$ 431.76 million by 2027. This translates to a CAGR of approximately 10.6% during the forecast period.

    What segments are covered in this report?

    The US Prostate Cancer Nuclear Medicine Diagnostics Market report typically cover these key segments-

  • 类型 (SPECT, PET)
  • PET 产品 (F-18, C11, GA 68 PSMA)
  • What is the historic period, base year, and forecast period taken for US Prostate Cancer Nuclear Medicine Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the US Prostate Cancer Nuclear Medicine Diagnostics Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in US Prostate Cancer Nuclear Medicine Diagnostics Market?

    The US Prostate Cancer Nuclear Medicine Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Blue Earth Diagnostics Limited
  • Progenics Pharmaceuticals, Inc.
  • CURIUM
  • Telix Pharmaceuticals Ltd.
  • NCM-USA LLC
  • ABX Advanced Biochemical Compounds GmbH
  • Jubilant Radiopharma
  • Lantheus Medical Imaging, Inc.
  • Advanced Accelerator Applications (Novartis AG)
  • Theragnostics
  • Who should buy this report?

    The US Prostate Cancer Nuclear Medicine Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the US Prostate Cancer Nuclear Medicine Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.